title: Role of Academic Drug Discovery in the Quest for New CNS Therapeutics.
abstract: There was a greater than 50% decline in central nervous system (CNS) drug discovery and development programs by major pharmaceutical companies from 2009 to 2014. This decline was paralleled by a rise in the number of university led drug discovery centers, many in the CNS area, and a growth in the number of public-private drug discovery partnerships. Diverse operating models have emerged as the academic drug discovery centers adapt to this changing ecosystem.
authors.affiliation: GE Healthcare Life Sciences , Marlborough, Massachusetts 01752, United States.
authors.forename: Brian H
authors.initials: BH
authors.lastname: Yokley
authors.affiliation: Academic Drug Discovery Consortium, Baltimore, Maryland 21205, United States.
authors.forename: Matthew
authors.initials: M
authors.lastname: Hartman
authors.affiliation: Johns Hopkins Drug Discovery, Departments of Neurology, Neuroscience, Psychiatry, Medicine, and Oncology, Johns Hopkins School of Medicine , Baltimore, Maryland 21205, United States.
authors.forename: Barbara S
authors.identifier: 0000-0001-9814-4157
authors.initials: BS
authors.lastname: Slusher
mesh_terms: D000046:Academic Medical Centers; D000818:Animals; D002491:Central Nervous System Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002493:Central Nervous System Diseases / Q000188:drug therapy*; D055808:Drug Discovery; D004345:Drug Industry; D006801:Humans; D055818:Public-Private Sector Partnerships
chemical_list: D002491:Central Nervous System Agents
keywords: Academic drug discovery; public-private partnerships